{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:36:27Z","timestamp":1787495787928,"version":"build-2736575974"},"reference-count":24,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T00:00:00Z","timestamp":1329177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:p>After extensive literature review utilizing PubMed and Medline searches, we present a rare case of oxaliplatin-induced grade 3\/4 hepatocellular injury and ototoxicity. The patient is a 46-year-old female diagnosed with stage IIIC (pT3N2bM0) adenocarcinoma of the sigmoid colon. PET\/CT prior to surgery and chemotherapy was negative for distant metastatic disease and baseline liver-associated enzymes were within normal limits. Following sigmoidectomy, patient began adjuvant chemotherapy with 5-florouracil, leucovorin, and oxaliplatin (mFOLFOX-6). Cycle 1 was complicated only by refractory nausea. However, cycle 2 was complicated by vertigo with refractory nausea, tinnitus, and marked elevation in liver enzymes in a hepatocellular pattern. Extensive workup was negative and the etiology of her symptoms and grade 3\/4 hepatocellular injury was hypothesized to be the result of oxaliplatin. Aspartate aminotransferase and alanine aminotransferase decreased after two additional weeks off therapy and during cycle 3 in which oxaliplatin was held. She had no evidence of 5-florouracil toxicity. On cycle 4, oxaliplatin was restarted at 50% dose; symptoms and liver-associated enzymes remained stable. However, oxaliplatin was increased up to 75% full dose for cycle 5 with reported vertigo, tinnitus, nausea, and return of elevation in liver-associated enzymes. Oxaliplatin is a chemotherapy agent widely used in the treatment of many malignancies including colon cancer. Side effects include peripheral neuropathy, gastrointestinal toxicity, neutropenia, grade 1\/2 hepatocellular injury, and hepatic vascular lesions. However, grade 3\/4 hepatocellular injury and ototoxicity are extremely rare with the administration of oxaliplatin. Therefore, we present the unusual chemotherapy side effects.<\/jats:p>","DOI":"10.1177\/1078155212437901","type":"journal-article","created":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T23:23:01Z","timestamp":1329261781000},"page":"355-359","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["Oxaliplatin-induced hepatocellular injury and ototoxicity: A review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent"],"prefix":"10.1177","volume":"18","author":[{"given":"Nicole O","family":"Vietor","sequence":"first","affiliation":[{"name":"Brooke Army Medical Center, San Antonio Uniformed Services Health Education Consortium, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J","family":"George","sequence":"additional","affiliation":[{"name":"Brooke Army Medical Center, San Antonio Uniformed Services Health Education Consortium, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2012,2,14]]},"reference":[{"key":"bibr1-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.2938"},{"key":"bibr2-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032709"},{"key":"bibr3-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073149"},{"key":"bibr4-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9930"},{"key":"bibr5-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2739"},{"key":"bibr6-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.136"},{"key":"bibr7-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1007\/BF00684890"},{"key":"bibr8-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008200825886"},{"key":"bibr9-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.35524"},{"key":"bibr10-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1188\/06.CJON.227-229"},{"key":"bibr11-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2004.16.6.595"},{"key":"bibr12-1078155212437901","first-page":"5113","volume":"12","author":"Butt W","year":"2010","journal-title":"Anticancer Res"},{"key":"bibr13-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-009-9263-3"},{"key":"bibr14-1078155212437901","unstructured":"Sanofi-aventis. Eloxatin (oxaliplatin) product information, 2002."},{"key":"bibr15-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3074"},{"key":"bibr16-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh095"},{"key":"bibr17-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181dc242c"},{"key":"bibr18-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1016\/S0399-8320(06)73542-4"},{"key":"bibr19-1078155212437901","first-page":"356","volume":"12","author":"Moroso M","year":"1983","journal-title":"J Otolaryngol"},{"key":"bibr20-1078155212437901","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199614030-00006"},{"key":"bibr21-1078155212437901","first-page":"19","volume":"66","author":"Reddel R","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"bibr22-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2006.09.006"},{"key":"bibr23-1078155212437901","first-page":"14","volume":"22","author":"Montaguti M","year":"2002","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"bibr24-1078155212437901","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155212437901","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155212437901","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155212437901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:14:31Z","timestamp":1777688071000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155212437901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,14]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1177\/1078155212437901"],"URL":"https:\/\/doi.org\/10.1177\/1078155212437901","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,14]]}}}